(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.11%) $83.47
(-0.04%) $2.48
(0.16%) $2 342.70
(0.51%) $29.77
(0.52%) $993.80
(0.05%) $0.931
(0.16%) $10.66
(0.04%) $0.791
(0.00%) $86.75
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
Today's Volume | 177 180 |
Average Volume | 368 932 |
Market Cap | 74.11M |
EPS | $-0.330 ( Q1 | 2024-05-10 ) |
Next earnings date | ( $-0.290 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.790 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0100 (0.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-26 | Oliviero James F Iii | Sell | 24 610 | COMMON STOCK |
2024-06-26 | Oliviero James F Iii | Sell | 37 890 | COMMON STOCK |
2024-06-26 | Gray William Garrett | Sell | 13 038 | Common Stock |
2024-05-24 | Gray William Garrett | Buy | 540 000 | Common Stock (Restricted) |
2024-05-24 | Oliviero James F Iii | Buy | 1 660 000 | COMMON STOCK (RESTRICTED) |
INSIDER POWER |
---|
60.79 |
Last 98 transactions |
Buy: 6 795 010 | Sell: 2 143 201 |
Volume Correlation
Checkpoint Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
RGP | 0.848 |
GDYN | 0.846 |
HDL | 0.845 |
HOFT | 0.841 |
BBCP | 0.84 |
BSET | 0.834 |
POAI | 0.833 |
QTRX | 0.832 |
RCKT | 0.828 |
MDXG | 0.826 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Checkpoint Therapeutics Correlation - Currency/Commodity
Checkpoint Therapeutics Financials
Annual | 2023 |
Revenue: | $103 000 |
Gross Profit: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
Revenue: | $103 000 |
Gross Profit: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
Revenue: | $192 000 |
Gross Profit: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators